Metergoline (INN , BAN ), also known as methergoline and sold under the brand names Contralac (veterinary) and Liserdol (clinical), is a monoaminergic medication of the ergoline group which is used as a prolactin inhibitor in the treatment of hyperprolactinemia (high prolactin levels) and to suppress lactation.[1][2][3]
Clinical data | |
---|---|
Trade names | Contralac, Liserdol |
Other names | Methergoline; FI-6337; [(8β)-1,6-Dimethylergolin-8-yl)methyl]carbamic acid phenylmethyl ester |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.037.881 |
Chemical and physical data | |
Formula | C25H29N3O2 |
Molar mass | 403.526 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Pharmacology
editPharmacodynamics
editMetergoline is a ligand of various serotonin and dopamine receptors.[4][5][6][7][8]
Site | Affinity (Ki [nM]) | Efficacy (Emax [%]) | Action |
---|---|---|---|
5-HT1A | 4.3 | ? | Agonist |
5-HT1B | 5.2–36 | ? | Partial agonist |
5-HT1D | 0.60–11.7 | ? | Partial agonist |
5-HT1E | 776–1,122 | ? | ? |
5-HT1F | 339–341 | ? | ? |
5-HT2A | 0.12–2.3 | ? | Antagonist |
5-HT2B | 0.71–1.8 | ? | Antagonist |
5-HT2C | 0.18–1.8 | ? | Antagonist |
5-HT3 | >5,000–7,400 | ? | ? |
5-HT4 | 354 | ? | ? |
5-HT5A | 630 | ? | ? |
5-HT5B | 1,000 | ? | ? |
5-HT6 | 61–400 | ? | ? |
5-HT7 | 6.4–6.5 | ? | Antagonist |
D2 | ? | ? | Agonist |
Notes: All sites are human except 5-HT3 (rat/pig), 5-HT4 (pig), and 5-HT5B (rat—no human counterpart).[4] |
References
edit- ^ Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 661–. ISBN 978-3-88763-075-1.
- ^ Plumb DC (21 February 2018). "Metergoline". Plumb's Veterinary Drug Handbook: Pocket. John Wiley & Sons. pp. 1057–. ISBN 978-1-119-34649-4.
- ^ Johson CA (2 December 2008). "False Pregnancy, Disorders of Pregnancy and Parturition, and Mismating". In Nelson RW, Couto CG (eds.). Small Animal Internal Medicine - E-Book. Elsevier Health Sciences. pp. 927–. ISBN 978-0-323-06512-2.
- ^ a b c "PDSP Database - UNC". pdsp.unc.edu. Archived from the original on 16 April 2021. Retrieved 15 January 2022.
- ^ a b Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, et al. (June 1994). "International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin)". Pharmacological Reviews. 46 (2): 157–203. PMID 7938165.
- ^ Hamon M, Mallat M, Herbet A, Nelson DL, Audinot M, Pichat L, Glowinski J (February 1981). "[3H]Metergoline: a new ligand of serotonin receptors in the rat brain". Journal of Neurochemistry. 36 (2): 613–626. doi:10.1111/j.1471-4159.1981.tb01634.x. PMID 7463079. S2CID 20259621.
- ^ Miller KJ, King A, Demchyshyn L, Niznik H, Teitler M (September 1992). "Agonist activity of sumatriptan and metergoline at the human 5-HT1D beta receptor: further evidence for a role of the 5-HT1D receptor in the action of sumatriptan". European Journal of Pharmacology. 227 (1): 99–102. doi:10.1016/0922-4106(92)90149-P. PMID 1330643.
- ^ a b Webster J (December 1999). "Dopamine agonist therapy in hyperprolactinemia". The Journal of Reproductive Medicine. 44 (12 Suppl): 1105–1110. PMID 10649819.
- ^ Pertz H, Eich E (1999). "Ergot Alkaloids and their Derivatives as Ligands for Serotoninergic, Dopaminergic, and Adrenergic Receptors" (PDF). Ergot. pp. 432–462. doi:10.1201/9780203304198-21. ISBN 9780429219764. Archived from the original (PDF) on 2021-04-16.
- ^ Pauwels PJ (September 1997). "5-HT 1B/D receptor antagonists". General Pharmacology. 29 (3): 293–303. doi:10.1016/s0306-3623(96)00460-0. PMID 9378233.
- ^ Hutcheson JD, Setola V, Roth BL, Merryman WD (November 2011). "Serotonin receptors and heart valve disease--it was meant 2B". Pharmacology & Therapeutics. 132 (2): 146–157. doi:10.1016/j.pharmthera.2011.03.008. PMC 3179857. PMID 21440001.
External links
edit- Metergoline at the U.S. National Library of Medicine Medical Subject Headings (MeSH)